BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wüthrich RP. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010;5:1312-29. [PMID: 20498248 DOI: 10.2215/CJN.01360210] [Cited by in Crossref: 75] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Fry AM, Leaper MJ, Bayliss R. The primary cilium: guardian of organ development and homeostasis. Organogenesis 2014;10:62-8. [PMID: 24743231 DOI: 10.4161/org.28910] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
2 Liebau MC. An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr 2014;2:68. [PMID: 25050320 DOI: 10.3389/fped.2014.00068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
3 Wang W, Geng X, Lei L, Jia Y, Li Y, Zhou H, Verkman AS, Yang B. Aquaporin-3 deficiency slows cyst enlargement in experimental mouse models of autosomal dominant polycystic kidney disease. FASEB J 2019;33:6185-96. [PMID: 30768374 DOI: 10.1096/fj.201801338RRR] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gamberi C, Hipfner DR, Trudel M, Lubell WD. Bicaudal C mutation causes myc and TOR pathway up-regulation and polycystic kidney disease-like phenotypes in Drosophila. PLoS Genet 2017;13:e1006694. [PMID: 28406902 DOI: 10.1371/journal.pgen.1006694] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
5 Zhu P, Sieben CJ, Xu X, Harris PC, Lin X. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model. Hum Mol Genet 2017;26:158-72. [PMID: 28007903 DOI: 10.1093/hmg/ddw376] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
6 Cotton CU, Hobert ME, Ryan S, Carlin CR. Basolateral EGF receptor sorting regulated by functionally distinct mechanisms in renal epithelial cells. Traffic 2013;14:337-54. [PMID: 23205726 DOI: 10.1111/tra.12032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
7 Gupta S, Ozimek-Kulik JE, Phillips JK. Nephronophthisis-Pathobiology and Molecular Pathogenesis of a Rare Kidney Genetic Disease. Genes (Basel) 2021;12:1762. [PMID: 34828368 DOI: 10.3390/genes12111762] [Reference Citation Analysis]
8 Ma M, Gallagher AR, Somlo S. Ciliary Mechanisms of Cyst Formation in Polycystic Kidney Disease. Cold Spring Harb Perspect Biol 2017;9:a028209. [PMID: 28320755 DOI: 10.1101/cshperspect.a028209] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
9 Raman A, Reif GA, Dai Y, Khanna A, Li X, Astleford L, Parnell SC, Calvet JP, Wallace DP. Integrin-Linked Kinase Signaling Promotes Cyst Growth and Fibrosis in Polycystic Kidney Disease. J Am Soc Nephrol. 2017;28:2708-2719. [PMID: 28522687 DOI: 10.1681/asn.2016111235] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
10 Snyder DS, Tradtrantip L, Yao C, Kurth MJ, Verkman AS. Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J Med Chem 2011;54:5468-77. [PMID: 21707078 DOI: 10.1021/jm200505e] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
11 Uversky VN, Davé V, Iakoucheva LM, Malaney P, Metallo SJ, Pathak RR, Joerger AC. Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev 2014;114:6844-79. [PMID: 24830552 DOI: 10.1021/cr400713r] [Cited by in Crossref: 172] [Cited by in F6Publishing: 153] [Article Influence: 21.5] [Reference Citation Analysis]
12 Takakura A, Nelson EA, Haque N, Humphreys BD, Zandi-Nejad K, Frank DA, Zhou J. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet 2011;20:4143-54. [PMID: 21821671 DOI: 10.1093/hmg/ddr338] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 8.3] [Reference Citation Analysis]
13 Kuo IY, Brill AL, Lemos FO, Jiang JY, Falcone JL, Kimmerling EP, Cai Y, Dong K, Kaplan DL, Wallace DP, Hofer AM, Ehrlich BE. Polycystin 2 regulates mitochondrial Ca2+ signaling, bioenergetics, and dynamics through mitofusin 2. Sci Signal 2019;12:eaat7397. [PMID: 31064883 DOI: 10.1126/scisignal.aat7397] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
14 Li D, Sun L. MicroRNAs and Polycystic Kidney Disease. Kidney Med 2020;2:762-70. [PMID: 33319200 DOI: 10.1016/j.xkme.2020.06.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Nistala R, Raja A, Pulakat L. mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats. Can J Physiol Pharmacol 2017;95:281-7. [PMID: 28177677 DOI: 10.1139/cjpp-2016-0567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
16 Barker AR, Thomas R, Dawe HR. Meckel-Gruber syndrome and the role of primary cilia in kidney, skeleton, and central nervous system development. Organogenesis 2014;10:96-107. [PMID: 24322779 DOI: 10.4161/org.27375] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
17 Li Q, Zeng Y, Jiang Q, Wu C, Zhou J. Role of mTOR signaling in the regulation of high glucose-induced podocyte injury. Exp Ther Med 2019;17:2495-502. [PMID: 30906437 DOI: 10.3892/etm.2019.7236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
18 Yamaguchi T, Reif GA, Calvet JP, Wallace DP. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol 2010;299:F944-51. [PMID: 20810616 DOI: 10.1152/ajprenal.00387.2010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
19 Saigusa T, Dang Y, Mullick AE, Yeh ST, Zile MR, Baicu CF, Bell PD. Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. FASEB J 2016;30:370-9. [PMID: 26391272 DOI: 10.1096/fj.15-279299] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
20 Wallace DP, White C, Savinkova L, Nivens E, Reif GA, Pinto CS, Raman A, Parnell SC, Conway SJ, Fields TA. Periostin promotes renal cyst growth and interstitial fibrosis in polycystic kidney disease. Kidney Int 2014;85:845-54. [PMID: 24284511 DOI: 10.1038/ki.2013.488] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
21 De Santis MC, Sala V, Martini M, Ferrero GB, Hirsch E. PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts. Cancers (Basel) 2017;9:E30. [PMID: 28353628 DOI: 10.3390/cancers9040030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
22 Romero-Garcia S, Lopez-Gonzalez JS, Báez-Viveros JL, Aguilar-Cazares D, Prado-Garcia H. Tumor cell metabolism: an integral view. Cancer Biol Ther 2011;12:939-48. [PMID: 22057267 DOI: 10.4161/cbt.12.11.18140] [Cited by in Crossref: 95] [Cited by in F6Publishing: 88] [Article Influence: 8.6] [Reference Citation Analysis]
23 Müller RU, Benzing T. Management of autosomal-dominant polycystic kidney disease-state-of-the-art. Clin Kidney J 2018;11:i2-i13. [PMID: 30581561 DOI: 10.1093/ckj/sfy103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
24 Takiar V, Caplan MJ. Polycystic kidney disease: pathogenesis and potential therapies. Biochim Biophys Acta 2011;1812:1337-43. [PMID: 21146605 DOI: 10.1016/j.bbadis.2010.11.014] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
25 Millet-Boureima C, He S, Le TBU, Gamberi C. Modeling Neoplastic Growth in Renal Cell Carcinoma and Polycystic Kidney Disease. Int J Mol Sci 2021;22:3918. [PMID: 33920158 DOI: 10.3390/ijms22083918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lin CH, Chao CT, Wu MY, Lo WC, Lin TC, Wu MS. Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis. Int Urol Nephrol 2019;51:2015-25. [PMID: 31578673 DOI: 10.1007/s11255-019-02292-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
27 Kipp KR, Kruger SL, Schimmel MF, Parker N, Shillingford JM, Leamon CP, Weimbs T. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol 2018;315:F395-405. [PMID: 29717938 DOI: 10.1152/ajprenal.00057.2018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
28 Gascue C, Katsanis N, Badano JL. Cystic diseases of the kidney: ciliary dysfunction and cystogenic mechanisms. Pediatr Nephrol 2011;26:1181-95. [PMID: 21113628 DOI: 10.1007/s00467-010-1697-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
29 Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, Song XW, Xu H, Mari S, Qian F, Pei Y, Musco G, Boletta A. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 2013;19:488-93. [PMID: 23524344 DOI: 10.1038/nm.3092] [Cited by in Crossref: 247] [Cited by in F6Publishing: 239] [Article Influence: 27.4] [Reference Citation Analysis]
30 Magyar Z, Schönleber J, Romics M, Hruby E, Nagy B, Sulya B, Beke A, Harmath Á, Jeager J, Rigó J Jr, Görbe É. Expression of VEGF in neonatal urinary obstruction: does expression of VEGF predict hydronephrosis? Med Sci Monit 2015;21:1319-23. [PMID: 25951999 DOI: 10.12659/MSM.894133] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Shillingford JM, Leamon CP, Vlahov IR, Weimbs T. Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol 2012;23:1674-81. [PMID: 22859856 DOI: 10.1681/ASN.2012040367] [Cited by in Crossref: 70] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
32 Kim HJ, Edelstein CL. Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside. Kidney Res Clin Pract 2012;31:132-8. [PMID: 26894018 DOI: 10.1016/j.krcp.2012.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
33 Olsan EE, Mukherjee S, Wulkersdorfer B, Shillingford JM, Giovannone AJ, Todorov G, Song X, Pei Y, Weimbs T. Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A 2011;108:18067-72. [PMID: 22025716 DOI: 10.1073/pnas.1111966108] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
34 Liu Y, Chen LH, Yuan YW, Li QS, Sun AM, Guan J. Activation of AKT is associated with metastasis of nasopharyngeal carcinoma. Tumour Biol 2012;33:241-5. [PMID: 22116667 DOI: 10.1007/s13277-011-0272-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
35 Pema M, Drusian L, Chiaravalli M, Castelli M, Yao Q, Ricciardi S, Somlo S, Qian F, Biffo S, Boletta A. mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Nat Commun 2016;7:10786. [PMID: 26931735 DOI: 10.1038/ncomms10786] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
36 van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, Mathijssen RHJ, Danser AHJ, Lang NN. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circ Res 2021;128:1040-61. [PMID: 33793337 DOI: 10.1161/CIRCRESAHA.121.318051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Verkman AS, Synder D, Tradtrantip L, Thiagarajah JR, Anderson MO. CFTR inhibitors. Curr Pharm Des 2013;19:3529-41. [PMID: 23331030 DOI: 10.2174/13816128113199990321] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
38 Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. J Cell Biol 2010;191:701-10. [PMID: 21079243 DOI: 10.1083/jcb.201006173] [Cited by in Crossref: 173] [Cited by in F6Publishing: 158] [Article Influence: 15.7] [Reference Citation Analysis]
39 Kanaan N, Devuyst O, Pirson Y. Renal transplantation in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2014;10:455-465. [PMID: 24935705 DOI: 10.1038/nrneph.2014.104] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]